There are several reasons that the incidence of TST in PNH will decrease over time: (i) eculizumab, a humanized monoclonal antibody against C5, blocks complement-mediated intravascular hemolysis [24] and considerably decreases the risk of thrombosis [18]. Here, C5 is linked to hemolysis.